Melanoma-associated suppression of the dendritic cell lines DC2.4 and Jawsii

American Journal of Immunology

Volumn 8, Issue 4, 2012, Pages 179-190

  Hargadon, Kristian Michael ^a   Tarekegne Ararso, Yonathan ^a   Forrest, Osric Anthony ^a   Mason Harte, Chad ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

Dendritic cell; Melanoma; Tumor immunity

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ACTIVATION; CELL MATURATION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; PROTEIN EXPRESSION; TUMOR IMMUNITY;

EID: 84876837324     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2012.179.190     Document Type: Article

References (49)

1. + T cells. Nat. Immunol., 2: 1010-1017. PMID: 11590405
2. Almand, B., J.I. Clark, E. Nikitina, B.J. Van and N.R. English et al., 2001. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol., 166: 78-689. PMID: 11123353
3. Alshamsan, A., S. Hamdy, S. Das, A. Lavasanifar and J. Samuel et al., 2010. Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J. Pharm. Pharmaceut. Sci., 13: 21-26. PMID: 20456827
4. Anichini, A., A. Scarito, A. Molla, G. Parmiani and R. Mortarini, 2003. Differentiation of CD8+ T cells from tumor invaded and tumor-free lymph nodes of melanoma patients: Role of common gamma-chain cytokines. J. Immunol., 171: 2134-2141. PMID: 12902520
5. Banchereau, J. and R.M. Steinman, 1998. Dendritic cells and the control of immunity. Nature, 392: 245-252. PMID: 9521319
6. Blohm, U., E. Roth, K. Brommer, T. Dumrese and F.M. Rosenthal et al., 2002. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J. Immunol., 169: 5522-5530. PMID: 12421928
7. Broek, L.V.D., D. Kagi, F. Ossendorp, R. Toes and S. Vamvakas et al., 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med., 184: 1781-1790. PMID: 8920866
8. Dong, H., S.E. Strome, D.R. Salomao, H. Tamura and F. Hirano et al., 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med., 8: 793-800. PMID: 12091876
9. Ferguson, A.R., L.A. Nichols, A.L. Zarling, E.D. Thompson and C.C. Brinkman et al., 2008. Strategies and challenges in eliciting immunity to melanoma. Immunol. Rev., 222: 28-42. PMID: 18363993
10. Fidler, I.J., 1975. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res., 35: 218-224. PMID: 1109790
11. Filatenkov, A.A., E.L. Jacovetty, U.B. Fischer, J.M. Curtsinger and M.F. Mescher et al., 2006. CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J. Immunol., 174: 6909-6917. PMID: 15905533
12. Fricke, I. and D.I. Gabrilovich, 2006. Dendritic cells and tumor microenvironment: A dangerous liaison. Immunol. Invest., 35: 459-483. PMID: 16916762
13. Garrido, F., T. Cabrera, M.A. Lopez-Nevot and F. Ruiz-Cabello, 1995. HLA class I antigens in human tumors. Adv. Cancer Res., 67: 155-195. PMID: 8571814
14. Geissmann, F., P. Revy, A. Regnault, Y. Lepelletier and M. Dy et al., 1999. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol., 162: 4567-4575. PMID: 10201996
15. Hahne, M., D. Rimoldi, M. Schroter, P. Romero and M. Schreier et al., 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science, 274: 1363-1366. PMID: 8910274
16. Hargadon, K.M., C.C. Brinkman, S.L. Sheasley-O'neill, L.A. Nichols and T.N. Bullock et al., 2006. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J. Immunol., 177: 6081-6090. PMID: 7056534
17. Hargadon, K.M., O.A. Forrest and P.R. Reddy, 2012. Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors. Cell. Immunol., 272: 275-282. PMID: 22051048
18. He, T., C. Tang, S. Xu, T. Moyana and J. Xiang, 2007. Interferon γ stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cell. Mol. Immunol., 4: 105-111. PMID: 17484804
19. Helden, S.V., F.V. Leeuwen and C. Figdor, 2008. Human and murine model cell lines for dendritic cell biology evaluated. Immunol. Lett., 117: 191-197. PMID: 18384885
20. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res., 66: 1123-1131. PMID: 16424049
21. Ilkovitch, D. and D.M. Lopez, 2008. Immune modulation by melanoma-derived factors. Exp. Dermatol., 17: 977-985. PMID: 18643844
22. Janeway, C.A. Jr. and R. Medzhitov, 2002. Innate immune recognition. Annu. Rev. Immunol., 20: 197-216. PMID: 11861602
23. Jiang, X., C. Shen, J. Rey-Ladino, H. Yu and R.C. Brunham, 2008. Characterization of murine dendritic cell line JAWSII and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect. Immun., 76: 2392-2401. PMID: 18362126
24. Joffre, O., M.A. Nolte, R. Sporri and C. Reis e Sousa, 2009. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev., 227: 234-247. PMID: 19120488
25. Koneru, M., D. Schaer, N. Monu, A. Ayala and A.B. Frey, 2005. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J. Immunol., 174: 1830-1840. PMID: 15699109
26. Kusmartsev, S., Y. Nefedova, D. Yoder and D.I. Gabrilovich, 2004. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol., 172: 989-999. PMID: 14707072
27. Lin, A., A. Schildknecht, L.T. Nguyen and P.S. Ohashi, 2010. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett., 127: 77-84. PMID: 19778555
28. MacKay, V. and E. Moore, 1997. Immortalized dendritic cells. U.S. Patent.
29. Matzinger, P., 1994. Tolerance, danger and the extended family. Annu. Rev. Immunol., 12: 991-1045. PMID: 8011301
30. Mortarini, R., A. Piris, A. Maurichi, A. Molla and I. Bersani et al., 2003. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res., 63: 2535-2545. PMID: 12750277
31. Olson, T.S. and K. Ley, 2002. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regulatory Integr. Comp. Physiol., 283: R7-R28. PMID: 12069927
32. Ostrand-Rosenberg, S. and P. Sinha, 2009. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol., 182: 4499-4506. PMID: 19342621
33. Peter, I., A. Mezzacasa, P. LeDonne, R. Dummer and S. Hemmi, 2001. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res., 11: 21-30. PMID: 11254112
34. Rabinovich, G., D. Gabrilovich and E. Sotomayor, 2007. Immunosuppressive Strategies that are Mediated by Tumor Cells. Annu. Rev. Immunol., 25: 267-296. PMID: 17134371
35. Radoja, S., M. Saio, D. Schaer, M. Koneru and S. Vukmanovic et al., 2001. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol., 167: 5042-5051. PMID:11673513
36. Re, F. and J.L. Strominger, 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem., 276: 37692-37699. PMID: 11477091
37. Restifo, N.P., F. Esquivel, Y. Kawakami, J.W. Yewdell and J.J. Mule et al., 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272. PMID: 8426105
38. Rhule, A., B. Rase, J.R. Smith and D.M. Shepherd, 2008. Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng. J. Ethnopharmacol., 116: 179-186. PMID: 18164154
39. Rosenberg, S.A. and D.E. White, 1996. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis. Tumor Immunol., 19: 81-84. PMID: 8859727
40. Sallusto, F., D. Lenig, C.R. Mackay and A. Lanzavecchia, 1998. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med., 187: 875-883. PMID: 9500790
41. Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White and P.E. Swanson et al., 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410: 1107-1111. PMID: 11323675
42. Shen, Z., G. Reznikoff, G. Dranoff and K. Rock, 1997. Cloned dendritic cells can present exogenous antigens on both MHC Class I and MHC Class II Molecules. J. Immunol., 158: 2723-2730. PMID: 9058806
43. Sousa, C.R., 2006. Dendritic cells in a mature age. Nat. Rev. Immunol., 6: 476-483. PMID: 16691244
44. Terabe, M., S. Matsui, J.M. Park, M. Mamura and N. Noben-Trauth et al., 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J. Exp. Med., 198: 1741-1752. PMID: 14657224
45. Whiteside, T.L., 2004. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol. Immunother, 53: 865-878. PMID: 15118842
46. Yamaguchi, Y., H. Tsumura, M. Miwa and K. Inaba, 1997. Contrasting effects of TGF-beta 1 and TNFalpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells, 15: 144-153. PMID: 9090791
47. Yamshchikov, G., L. Thompson, W.G. Ross, H. Galavotti and W. Aquila et al., 2001. Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations. Clin. Cancer Res., 7: 909s-916s. PMID: 11300491
48. Yang, L. and D.P. Carbone, 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res., 92: 13-27. PMID: 15530555
49. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley and D. Lienard et al., 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res., 64: 2865-2873. PMID: 15087405